Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Druggable signaling proteins.

Mouldy Sioud1, Marianne Leirdal

  • 1Department of Immunology, Institute for Cancer Research, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway.

Methods in Molecular Biology (Clifton, N.J.)
|December 19, 2006
PubMed
Summary

Aberrantly activated signaling pathways drive cancer. Targeting key proteins like tyrosine kinases offers a promising strategy for developing effective anticancer drugs by reversing disease phenotypes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Engineering Immunity: Current Progress and Future Directions of CAR-T Cell Therapy.

International journal of molecular sciences·2026
Same author

RNA Therapeutics: Bridging Discovery and Clinical Implementation.

Methods in molecular biology (Clifton, N.J.)·2025
Same author

Molecular Mechanisms of Innate Immune Sensing of Exogenous RNAs.

Methods in molecular biology (Clifton, N.J.)·2025
Same author

Effects of Nucleoside Modifications on mRNA Translation: Choosing the Right Modifications.

Methods in molecular biology (Clifton, N.J.)·2025
Same author

Assessing the Immunogenicity of Synthetic RNA Using Blood Cells.

Methods in molecular biology (Clifton, N.J.)·2025
Same author

Large-Scale Production of Unmodified mRNA for Reprogramming Human Dendritic Cells and T Cells.

Methods in molecular biology (Clifton, N.J.)·2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Cellular signaling pathways are crucial for normal function but aberrant activation can lead to diseases like cancer.
  • Key signaling proteins frequently deregulated in tumors include epidermal growth factor receptor family, Ras proteins, and BCR-ABL fusion protein.

Purpose of the Study:

  • To summarize validated and druggable targets in aberrant signaling pathways implicated in cancer.
  • To highlight the therapeutic potential of targeting these activated signaling proteins for anticancer drug development.

Main Methods:

  • Review of in vitro and in vivo studies demonstrating the effects of blocking key signaling targets.
  • Analysis of therapeutic advances in cancer therapy focusing on targeted agents.

Main Results:

  • Blocking key targets in constitutively activated signaling pathways can reverse disease phenotypes.
  • Constitutive activation of specific targets is sufficient to induce disease phenotypes.
  • Targeted therapies against active tyrosine kinases, such as imatinib and gefitinib, have shown significant success.

Conclusions:

  • Deregulation of specific signaling proteins is a hallmark of cancer, presenting opportunities for targeted therapies.
  • Targeting activated signaling pathways, particularly tyrosine kinases, represents a successful strategy in modern cancer treatment.

Related Experiment Videos